Scientists at the University of Illinois Chicago found a cancer-fighting weapon hiding in the last place anyone expected — inside the tumors themselves.
Story Snapshot
- Researchers pulled a protein from bacteria living inside tumors and turned it into a lab-made peptide called aurB.
- aurB enters cancer cell mitochondria and shuts down ATP production, cutting off the tumor’s energy supply.
- In prostate cancer animal tests, aurB combined with radiation significantly slowed tumor growth with no clear signs of toxicity.
- The university has secured a patent, and the team plans to pursue human clinical trials.
Bacteria Living Inside Tumors Became the Source of a New Cancer Treatment
Tumors are not empty masses of rogue cells. They are crowded environments full of bacteria, immune cells, and other biological activity. University of Illinois Chicago researchers looked closely at the bacteria living inside tumors and found something useful. One bacterial protein, called auracyanin, turned out to have properties worth studying. The team built a lab-made version of a piece of that protein and named it aurB. That decision opened a new line of attack against cancer.
The aurB peptide works by sneaking inside cancer cell mitochondria — the parts of the cell that make energy. Once inside, aurB binds to ATP synthase, the machine that produces ATP, which is the fuel cells run on. Block that machine, and the cancer cell starves. This approach is different from chemotherapy, which attacks cancer cells more directly and often damages healthy tissue along the way. Targeting energy production is a smarter, more focused strategy — at least in theory.
Animal Test Results Were Strong Enough to Earn a Patent
The research team tested aurB in prostate cancer animal models, specifically using a tibial bone metastatic model that mimics how prostate cancer spreads to bone. When they combined aurB with radiation, tumor growth dropped significantly. The animals showed no clear signs of toxicity during the study. Senior author Tohru Yamada, PhD, described the tumor growth inhibition as significant. The University of Illinois Chicago’s Office of Technology Management agreed — they secured a patent on aurB.
The tests focused on hormone therapy-resistant prostate cancer with inactive p53 genes. That matters because those are some of the hardest cases to treat. Standard hormone therapy stops working, and p53 is a gene that normally helps suppress tumors. When it goes inactive, cancer becomes more aggressive. The fact that aurB showed results in that specific, difficult context makes the findings more meaningful, not less.
Bacterial Cancer Therapy Has a Long History of Promise and Slow Progress
Using bacteria to fight cancer is not a new idea. Researchers have explored bacterial species like Salmonella, Clostridium, and Lactobacillus in cancer therapy for decades. Some approaches have reached clinical trials. Most have stalled somewhere between promising animal data and proven human results. The pattern is familiar: strong preclinical results, institutional caution, regulatory hurdles, and long timelines. aurB fits neatly into that history, which is both encouraging and sobering.
Scientists at the University of Illinois Chicago have turned an unlikely source into a potential new weapon against cancer: bacteria that naturally live inside tumors. They developed a peptide called aurB, inspired by a bacterial protein, that infiltrates https://t.co/mL7JgerwUd
— Michael W. Deem (@Michael_W_Deem) July 8, 2026
What makes aurB stand out is the mechanism. Most bacterial cancer research focuses on immune system activation or direct tumor targeting. aurB goes after the energy supply. That is a different angle, and it pairs naturally with radiation therapy, which also stresses cancer cell energy systems. The combination approach showed the strongest results in the animal models. If that synergy holds up in humans, it could matter a great deal for patients who have run out of standard options.
What Comes Next Determines Whether This Discovery Saves Lives
The University of Illinois Chicago team has done the hard early work. They found an unexpected source, built a testable compound, ran rigorous animal studies, and published results in the peer-reviewed journal Signal Transduction and Targeted Therapy. They secured a patent. Now comes the harder part — raising money, designing human trials, and navigating Food and Drug Administration approval for a novel bacterial-derived peptide. None of that is fast. But the foundation is real, and the logic behind it is sound.
Sources:
scitechdaily.com, today.uic.edu, academicjobs.com
